Advertisement

 

 

SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells.

SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells.
Author Information (click to view)

Ordonez P, Kunzelmann S, Groom HC, Yap MW, Weising S, Meier C, Bishop KN, Taylor IA, Stoye JP,


Ordonez P, Kunzelmann S, Groom HC, Yap MW, Weising S, Meier C, Bishop KN, Taylor IA, Stoye JP, (click to view)

Ordonez P, Kunzelmann S, Groom HC, Yap MW, Weising S, Meier C, Bishop KN, Taylor IA, Stoye JP,

Advertisement

Scientific reports 2017 02 217() 42824 doi 10.1038/srep42824

Abstract

SAMHD1 is an intracellular enzyme that specifically degrades deoxynucleoside triphosphates into component nucleoside and inorganic triphosphate. In myeloid-derived dendritic cells and macrophages as well as resting T-cells, SAMHD1 blocks HIV-1 infection through this dNTP triphosphohydrolase activity by reducing the cellular dNTP pool to a level that cannot support productive reverse transcription. We now show that, in addition to this direct effect on virus replication, manipulating cellular SAMHD1 activity can significantly enhance or decrease the anti-HIV-1 efficacy of nucleotide analogue reverse transcription inhibitors presumably as a result of modulating dNTP pools that compete for recruitment by viral polymerases. Further, a variety of other nucleotide-based analogues, not normally considered antiretrovirals, such as the anti-herpes drugs Aciclovir and Ganciclovir and the anti-cancer drug Clofarabine are now revealed as potent anti-HIV-1 agents, under conditions of low dNTPs. This in turn suggests novel uses for nucleotide analogues to inhibit HIV-1 in differentiated cells low in dNTPs.

Submit a Comment

Your email address will not be published. Required fields are marked *

2 × five =

[ HIDE/SHOW ]